BioMark Diagnostics, Inc. to present at the inaugural Small-Cap Stars Conference at the NASDAQ MarketSite on December 18, 2014

Vancouver, British Columbia, Dec. 16, 2014 (GLOBE NEWSWIRE) -- BioMark Diagnostics Inc. ("BioMark" or the "Company") (CSE: BUX, FSE:20B) is excited to announce that it will be presenting at the inaugural Small-Cap Stars Conference at the world-famous NASDAQ MarketSite on December 18, 2014.

The event is a gathering of the brightest emerging growth NASDAQ-listed small-cap companies to present and network with an exclusive group of top-level institutional investors. The Small-Cap Stars Conference is highlighted with a keynote presentation by legendary money manager and small-cap pioneer Ken Fisher, CEO of Fisher Investments. There will also be a special guest presentation by Rock & Roll Hall of Famer Gene Simmons, a New York Times best-selling author and Master of Brand Identity.

President and CEO of BioMark, Rashid Ahmed comments: "The equities conference provides us with an outstanding venue to update our investors and provides us with unparalleled access to major US institutions that understand the potential in the biopharma sector for Companies with advanced diagnostics solutions."

To learn more about BioMark Diagnostics, Inc., we encourage you to follow our Issuer Profile on, and to visit our website at .

The event is for an institutional audience only. Attendees will include: Hedge Funds, Family Offices, Portfolio Managers, Investment Banks & Venture Capitalists interested in small-cap opportunities on the NASDAQ. One-on-One meetings are available for company management teams and qualified investors. designed this full-day event dedicated to creating unparalleled discovery and exclusive networking sessions, including our Holiday Cocktail party to cap off the conference. For more details on the conference, please visit

To learn more about or to become a member of our online financial community, please visit:

About BioMark Diagnostics Inc.

BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

About, Inc. is an online financial publication and social community for self-directed investors, public and private companies, market experts, and professional service providers across the global capital markets. The Issuer Dashboard is an ideal SaaS platform to effectively manage corporate communication and investor awareness campaigns, engage with market intermediaries and financial advisors, and research industry peers. Registered members can leverage our market-leading commentary and content curation, as well as our proprietary research tools, such as theSmall-Cap Stars, which spotlights promising growth companies through our institutional-quality algorithms, and our robust do-it-yourself Equities Valuation Analysis (E.V.A.) research reports. Go to to become a member.

Further information about BioMark is available under its profile on the SEDAR website and on the CSE website

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

CONTACT: For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: Source:BioMark Diagnostics, Inc.